Inspired by Patients, Every day.

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

Inspired by Patients, Every day.

Karyopharm Therapeutics is an innovation-driven pharmaceutical company focused on the discovery, development, and commercialization of medicines with the goal of improving the lives of patients with cancer and other major diseases.

XPO1 Inhibition & SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.

XPO1 Inhibition & SINE Technology

Karyopharm is the industry leader in oral Selective Inhibitor of Nuclear Export (SINE) technology, developed to address a fundamental mechanism of oncogenesis. Oncogenesis is the process through which healthy cells become transformed into cancer cells.

Karyopharm Pipeline

With four unique drug candidates in clinical development, Karyopharm is developing medicines that target patients with cancer in both hematologic and solid tumors.

Karyopharm Pipeline

With four unique drug candidates in clinical development, Karyopharm is developing medicines that target patients with cancer in both hematologic and solid tumors.

Our Commitment to Patients

At Karyopharm, patients are at the core of everything we do. They inspire us, keep us motivated, and are critical in our pursuit of developing important new medicines.

Our Commitment to Patients

At Karyopharm, patients are at the core of everything we do. They inspire us, keep us motivated, and are critical in our pursuit of developing important new medicines.

Karyopharm Clinical Trials

Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.

Karyopharm Clinical Trials

Karyopharm has ongoing clinical trials for our lead drug candidate and next-generation programs in earlier lines of treatment, in combination trials, and in a variety of tumor types across both hematologic and solid tumors.

Join The Karyopharm Team

“If you work hard and show the initiative, you are trusted to pursue your professional curiosities, and can be rewarded with work experiences usually reserved for more senior employees. I’ve been well-versed with new skills, and I got to be part of an initiative that might otherwise be considered above my pay grade at another organization.  Karyopharm accomplishes so much that the excitement is infectious, and I have no doubt I will have a fruitful career here”

Alan Finance Senior Manager – R&D

“It means a lot to a scientist like me who can help a company develop a drug and hopefully get it approved to be able to reach the cancer patients who need it most – every day we try to transition science into development, turn strategy into execution, and ultimately try to turn a molecule into a pill that can help treat multiple cancers.”

Hongmei Executive Director, Clinical Pharmacology & DMPK

“As the VP of Data Sciences, the role of my team and of myself is to advance Karyopharm drug discovery and development programs by utilizing our knowledge in data. Throughout my four years at the company, I have been able to work on all of our clinical studies and regulatory submissions. These types of opportunities to help patients with unmet medical needs makes me realize that my work is so meaningful and so important.”

Shijie VP, Data Sciences – Biostatistics
Alan
Hongmei
Shije